In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Athelas Ltd.

Executive Summary

Geneva-based start up Athelas Ltd. aims to develop anti-infective drugs based on new bacterial targets it discovers through its DiVi platform. The company's platform is based on the use of the amoeba as a model organism--by engineering single-gene mutant bacteria and infecting the amoebas with those bacteria, Athelas' scientists aim to identify drug targets that may be important in vivo, but that might not be found via traditional in vitro screening methods.

You may also be interested in...



Antibacterials: Biotechs Fill the Big Pharma Void

Big Pharma may have abandoned anti-bacterial research some years ago, but biotechs are filling the void. Their approaches range from improving existing drugs to discovering entirely new targets. Yet although a handful in Europe, including recently floated Basilea and private firm Arrow, has attracted recent investor interest, it hasn't been the anti-bacterials per se that have drawn them in. Basilea benefited from its spin-off status; Arrow from a promising anti-viral project and broad portfolio. Despite growing concerns over bacterial resistance, the field needs success stories to draw investors back for good. Even then, the nature of the diseases and therapies under development mean it's likely to remain the domain of smaller firms.

QSI Pharma AS

QSI Pharma, a Danish start up formed by the Technical University of Denmark and the biotech incubator of Leo Pharma AS, aims to inhibit the formation of deadly biofilms, highly structured and virulent communities of surface colonizing bacteria. QSI aims to discover molecules that interfere with bacterial quorum sensing, a cell-cell signaling process by which bacteria form biofilms when sufficient bacteria have amassed. The company's first target is Pseudomonas aeruginosa, which is responsible for a significant percentage of deaths from many hospital-acquired infections.

QSI Pharma AS

QSI Pharma, a Danish start up formed by the Technical University of Denmark and the biotech incubator of Leo Pharma AS, aims to inhibit the formation of deadly biofilms, highly structured and virulent communities of surface colonizing bacteria. QSI aims to discover molecules that interfere with bacterial quorum sensing, a cell-cell signaling process by which bacteria form biofilms when sufficient bacteria have amassed. The company's first target is Pseudomonas aeruginosa, which is responsible for a significant percentage of deaths from many hospital-acquired infections.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel